Clinical Trial: A Prospective, Open-Label, Single-Center, Single-Arm Phase II Clinical Trial of Iparomlimab and Tuvonralimab in Combination With TCb (Paclitaxel/Nab-Paclitaxel/Docetaxel + Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer (China)

China, Sept. 22 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Prospective, Open-Label, Single-Center, Single-Arm Phase II Clinical Trial of Iparomlimab and Tuvonralimab in Combination With TCb (Paclitaxel/Nab-Paclitaxel/Docetaxel + Carboplatin) as Neoadjuvant Therapy for Triple-Negative Breast Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600133049

Registration Time: 2026/09/21

Type: Interventional study

Primary Sponsor: The First Hospital of China Medical University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=343224

Published by HT Digital Content Services with permission from Health Daily Digest....